New antiretroviral tactics: transitions or mere trends? An interview with Joep Lange,MD,PhD. Interview by Mark Mascolini.
Mascolini
M
M
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced; D009426:Netherlands; D012109:Research Support as Topic; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016879:Salvage Therapy; D014481:United States; D019562:Viral Load; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors